Months 2019–2020 | N (%) | Anti-SARS-CoV-2 positivity | Past infection | Recent infection | Univariate analysis | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No (%) | Yes (%) | p-value* | No (%) | Yes (%) | p-value* | No (%) | Yes (%) | p-value* | OR (95% CI) | p-value | ||
December/2019 | 25 (7.3) | 25 (100) | 0 (0.0) | < 0.001 | 25 (100) | 0 (0.0) | < 0.001 | 25 (100) | 0 (0.0) | 0.452 | 0 (0.0–0.0) | 0.998 |
January/2020 | 145 (42.3) | 144 (99.3) | 1 (0.7) | 145 (100) | 0 (0.0) | 144 (99.3) | 1 (0.7) | 0.03 (0.0–0.22) | 0.001 | |||
February/2020 | 42 (12.2) | 42 (100) | 0 (0.0) | 42 (100) | 0 (0.0) | 42 (100) | 0 (0.0) | 0 (0.0–0.0) | 0.997 | |||
July/2020 | 52 (15.2) | 51 (98.1) | 1 (1.9) | 52 (100) | 0 (0.0) | 51 (98.1) | 1 (1.9) | 0.08 (0.01–0.63) | 0.017 | |||
August/2020 | 24 (7.0) | 21 (87.5) | 3 (12.5) | 22 (91.7) | 2 (8.3) | 23 (95.8) | 1 (4.2) | 0.57 (0.14–2.27) | 0.426 | |||
September/2020 | 55 (16.0) | 44 (80.0) | 11 (20.0) | 46 (83.6) | 9 (16.4) | 53 (96.4) | 2 (3.6) | 1.00 | – |